ACE and congestive heart failure: Two studies attempted to determine whether an ARB added to an ACE inhibitor would contribute favourably to clinical outcomes in CHF.8,9 In the Valsartan Heart Failure Trial (Val-HeFT), the results indicated no significant reduction in mortality but a significant reduction in morbidity.9 These results seem to indicate the potential benefit of combining an ACE inhibitor with an ARB in CHF.